CASI Pharmaceuticals

CASI is a biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics addressing CANCER and other unmet medical needs for the global market, with a focus on China and the U.S.
Our mission is to become an integrated biopharmaceutical company with significant market share in China, while establishing partnerships for global development and commercialization. Part of our strategy is to leverage our expertise and resources in North America and China to bring safer, more effective, and/or easier-to-use drugs to patients and to develop them more cost-effectively and faster using our unique dual development approach.

Company Growth (employees)
Type
Public
HQ
Rockville, US
Size (employees)
20 (est)
CASI Pharmaceuticals is headquartered in Rockville, US

Key People/Management at CASI Pharmaceuticals

Ken Ren

Ken Ren

Chief Executive Officer
Sara Capitelli

Sara Capitelli

Vice President, Finance and Principal Accounting Officer

CASI Pharmaceuticals Office Locations

CASI Pharmaceuticals has offices in Rockville and Beijing
Rockville, US (HQ)
300 9620 Medical Center Dr
Beijing, CN
CASI (Beijing) Pharmaceuticals, Inc. FullLink Plaza Suite B1214, B1215 18 Chaoyangmenwai Street, Chaoyang

CASI Pharmaceuticals Financials and Metrics

CASI Pharmaceuticals Financials

CASI Pharmaceuticals's revenue was reported to be $47.7 k in FY, 2015
USD

Net income (Q1, 2017)

(1.7 m)

Market capitalization (19-Oct-2017)

141.5 m

Cash (31-Mar-2017)

25.5 m
CASI Pharmaceuticals's current market capitalization is $141.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

23.7 k47.7 k

Revenue growth, %

101%

Cost of goods sold

7.5 k6.3 k

Gross profit

16.3 k41.4 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cost of goods sold

6.3 k2.7 k

R&D expense

724.5 k697 k865 k1.2 m942.3 k1 m1.4 m1 m1 m

General and administrative expense

891.9 k1.2 m924.8 k857.6 k673.9 k765.1 k1.9 m676.9 k644.2 k

Operating expense total

1.6 m1.8 m1.8 m2.1 m1.6 m1.8 m3.3 m1.7 m1.7 m
USDY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

6.3 m4.9 m1.1 m8 m15.1 m10.7 m5.1 m27.1 m

Current Assets

15.4 m11 m5.6 m27.4 m

PP&E

78.1 k261.8 k218.8 k229.6 k

Total Assets

15.5 m11.3 m5.8 m27.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

13.1 m11.8 m9.5 m8 m6.4 m13.9 m18.5 m24.1 m25.5 m

Current Assets

13.2 m12.2 m9.9 m8.3 m6.8 m14.3 m18.8 m24.5 m25.9 m

PP&E

240.4 k230.6 k246.3 k245.3 k234.7 k222.8 k168.7 k184.1 k244.6 k

Total Assets

13.5 m12.4 m10.2 m8.6 m7.1 m14.5 m19 m24.8 m26.2 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(26.2 m)(7.2 m)(9.5 m)

Depreciation and Amortization

48.2 k68.4 k66.5 k

Accounts Receivable

(23.7 k)23.7 k

Accounts Payable

352.2 k129.5 k180.5 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(3.1 m)(24.6 m)(1.8 m)(2.1 m)(1.6 m)(1.8 m)(3.3 m)(1.7 m)(1.7 m)

Depreciation and Amortization

19.2 k32.7 k

Accounts Payable

171.1 k197.8 k994.9 k969 k801.3 k783.3 k945.8 k918.9 k1.1 m

Cash From Operating Activities

(1.9 m)(2.9 m)
Y, 2017

Financial Leverage

1.4 x
Show all financial metrics

CASI Pharmaceuticals Market Value History

Traffic Overview of CASI Pharmaceuticals

CASI Pharmaceuticals Company Life and Culture

You may also be interested in